Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 14/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.40 |
| ▸ | INSR | P06213 | 5/20 | 0.40 |
| ▸ | NPM1 | P06748 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526219 | 0.86 | EGFR (0.46) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL525944 | 0.85 | JAK2 (0.44) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL519657 | 0.80 | EGFR (0.46) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL526218 | 0.76 | JAK2 (0.46) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL520794 | 0.68 | DYRK3 (0.47) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL519570 | 0.68 | EGFR (0.46) | EGFRJAK2PTK2ALKINSR | |
| SCHEMBL520837 | 0.66 | ALK (0.59) | JAK2ALKINSR | |
| SCHEMBL16530860 | 0.66 | JAK2 (0.51) | JAK2PTK2ALKINSR | |
| SCHEMBL519764 | 0.66 | INSR (0.52) | JAK2ALKINSR | |
| SCHEMBL519982 | 0.65 | JAK2 (0.47) | EGFRJAK2PTK2ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | EGFR 1187/4885JAK2 1/4885PTK2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.